Table 7.
Complication by grade in 219 patients treated with transarterial chemoembolization for hepatocellular carcinoma.
| Total bilirubin | ||||
|---|---|---|---|---|
| Variable | TB < 2 (n = 179) |
TB 2–3 (n = 30) |
TB > 3 (n = 10) |
P-value |
| Non-laboratory based complications | 0.66 | |||
| None | 125 (125/179; 69.8%) | 18 (18/30; 60%) | 8 (8/10; 80%) | |
| Grade 1 | 43 (43/179; 24%) | 8 (8/30; 26.7%) | 2 (2/10; 20%) | |
| Grade 2 | 11 (11/179; 6.1%) | 4 (4/30; 13.3%) | 0 (0/10; 0%) | |
| Grade 3 | 2 (2/179; 1.1%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 4 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 5 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Total bilirubin change at 1 day | 0.71 | |||
| None | 174 (174/179; 97.1%) | 29 (29/30; 96.7%) | 10 (10/10; 100%) | |
| Grade 1 | 3 (3/179; 1.7%) | 1 (1/30; 3.3%) | 0 (0/10; 0%) | |
| Grade 2 | 1 (1/179; 0.6%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 3 | 1 (1/179; 0.6%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 4 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Total bilirubin change at 1 montha | 0.12 | |||
| None | 172 (172/179; 96%) | 28 (28/30; 93.4%) | 9 (9/10; 90%) | |
| Grade 1 | 5 (5/179; 2.8%) | 1 (1/30; 3.3%) | 1 (1/10; 10%) | |
| Grade 2 | 0 (0/179; 0%) | 1 (1/30; 3.3%) | 1 (1/10; 10%) | |
| Grade 3 | 1 (1/179; 0.6%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 4 | 1 (1/179; 0.6%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| AST change at 1 daya | 0.63 | |||
| None | 99 (99/179; 55.3%) | 21 (21/30; 70%) | 5 (5/10; 50%) | |
| Grade 1 | 28 (28/179; 15.7%) | 4 (4/30; 13.3%) | 1 (1/10; 10%) | |
| Grade 2 | 21 (21/179; 11.7%) | 3 (3/30; 10%) | 2 (2/10; 20%) | |
| Grade 3 | 35 (35/179; 19.6%) | 2 (2/30; 6.7%) | 3 (3/10; 30%) | |
| Grade 4 | 8 (8/179; 4.5%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| AST change 1 month | 0.66 | |||
| None | 163 (163/179; 91.1%) | 30 (30/30; 100%) | 9 (9/10; 90%) | |
| Grade 1 | 9 (9/179; 5%) | 0 (0/30; 0%) | 1 (1/10; 10%) | |
| Grade 2 | 5 (5/179; 2.8%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 3 | 1 (1/179; 1.1%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 4 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| ALT change 1 daya | 0.48 | |||
| None | 140 (140/179; 78.2%) | 28 (28/30; 93.4%) | 7 (7/10; 70%) | |
| Grade 1 | 15 (15/179; 8.4%) | 0 (0/30; 0%) | 2 (2/10; 20%) | |
| Grade 2 | 18 (18/179; 10%) | 1 (1/30; 3.3%) | 1 (1/10; 10%) | |
| Grade 3 | 9 (9/179; 5.1%) | 1 (1/30; 3.3%) | 0 (0/10; 0%) | |
| Grade 4 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| ALT change 1 month | 0.99 | |||
| None | 174 (174/179; 97.2%) | 30 (30/30; 100%) | 10 (10/10; 100%) | |
| Grade 1 | 4 (4/179; 2.2%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 2 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 3 | 1 (1/179; 0.6%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Grade 4 | 0 (0/179; 0%) | 0 (0/30; 0%) | 0 (0/10; 0%) | |
| Direct Bilirubin | ||||
| Variable | DB < 1 (n = 197) |
DB 1–2 (n = 17) |
P-value | |
| Non-laboratory based complicationsa | 0.58 | |||
| None | 135 (135/197; 68.5%) | 11 (11/17; 64.7%) | ||
| Grade 1 | 47 (47/197; 23.9%) | 6 (6/17; 35.3%) | ||
| Grade 2 | 15 (15/197; 7.6%) | 0 (0/17; 0%) | ||
| Grade 3 | 2 (2/197; 1%) | 0 (0/17; 0%) | ||
| Grade 4 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
| Grade 5 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
| Total bilirubin change at 1 day | 0.99 | |||
| None | 191 (191/197; 97%) | 17 (17/17; 100%) | ||
| Grade 1 | 4 (4/197; 2%) | 0 (0/17; 0%) | ||
| Grade 2 | 1 (1/197; 0.5%) | 0 (0/17; 0%) | ||
| Grade 3 | 1 (1/197; 0.5%) | 0 (0/17; 0%) | ||
| Grade 4 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
| Total bilirubin change at 1 montha | 0.69 | |||
| None | 189 (189/197; 96%) | 15 (15/17; 88.2%) | ||
| Grade 1 | 5 (5/197; 2.5%) | 2 (2/17; 11.8%) | ||
| Grade 2 | 1 (1/197; 0.5%) | 1 (1/17; 5.9%) | ||
| Grade 3 | 1 (1/197; 0.5%) | 0 (0/17; 0%) | ||
| Grade 4 | 1 (1/197; 0.5%) | 0 (0/17; 0%) | ||
| AST change at 1 daya | 0.69 | |||
| None | 111 (111/197; 56.3%) | 11 (11/17; 64.7%) | ||
| Grade 1 | 30 (30/197; 15.2%) | 3 (3/17; 17.6%3) | ||
| Grade 2 | 23 (23/197; 11.7%) | 2 (2/17; 11.8%) | ||
| Grade 3 | 35 (35/197; 17.8%) | 2 (2/17; 11.8%) | ||
| Grade 4 | 5 (5/197; 2.5%) | 0 (0/17; 0%) | ||
| AST change 1 month | 0.32 | |||
| None | 183 (183/197; 92.9%) | 15 (15/17; 88.2%) | ||
| Grade 1 | 9 (9/197; 4.6%) | 1 (1/17; 5.9%) | ||
| Grade 2 | 3 (3/197; 1.5%3) | 1 (1/17; 5.9%) | ||
| Grade 3 | 2 (2/197; 1%) | 0 (0/17; 0%) | ||
| Grade 4 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
| ALT change 1 daya | 0.95 | |||
| None | 157 (157/197; 79.7%) | 14 (14/17; 82.4%) | ||
| Grade 1 | 15 (15/197; 7.6%) | 1 (1/17; 5.9%) | ||
| Grade 2 | 19 (19/197; 9.6%) | 1 (1/17; 5.9%) | ||
| Grade 3 | 9 (9/197; 4.6%) | 1 (1/17; 5.9%) | ||
| Grade 4 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
| ALT change 1 month | 0.99 | |||
| None | 192 (192/197; 97.5%) | 17 (17/17; 100%) | ||
| Grade 1 | 4 (4/197; 2%) | 0 (0/17; 0%) | ||
| Grade 2 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
| Grade 3 | 1 (1/197; 0.5%) | 0 (0/17; 0%) | ||
| Grade 4 | 0 (0/197; 0%) | 0 (0/17; 0%) | ||
AST: aspartate aminotransferase; ALT: aminotransferase; TB: total bilirubin; DB: direct bilirubin. Variables are expressed as raw numbers. Numbers in parentheses are proportions followed by percentages.
a
Indicates some patients had more than one complication during multiple treatments of their HCC.